Exagen price target lowered to $9 from $10 at BTIG

BTIG analyst Mark Massaro lowered the firm’s price target on Exagen (XGN) to $9 from $10 and keeps a Buy rating on the shares. Q4 was in line with the company’s pre-announcement, but “the bigger update” was the 2026 revenue guidance that came in below consensus, the analyst tells investors. While the firm expects Exagen to drive high-single digit revenue growth in 2026, it adds that it expects the company to return to double-digit growth in 2027 and cross over to positive adjusted EBITDA.